DISA (SGX:532) has entered into a non-binding agreement to acquire 50% of an operator of a rheumatism and arthritis specialist medical center, according to a Monday filing on the Singapore Exchange.
The SG$5.5 million proposed acquisition involves a cash payment of SG$3 million and SG$2.5 million in newly issued DISA shares, priced at either the prevailing market price or a minimum that will be determined later.
The target company, established in 2003, is Singapore's only heartland-based center specializing in arthritis and rheumatism care, with FY24 revenue of SG$7.6 million and EBITDA of SG$2.1 million.
Completion depends on due diligence, funding, and approvals, with the seller committing to a 10-year practitioner role and maintaining a 50% stake.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。